预约演示

Huadong enters licence deal for MC2 Therapeutics MC2 Therapeutics’ Wynzora cream

2023-09-01

交易

引进/卖出

The cream is intended for topical treatment of plaque psoriasis, including scalp psoriasis. Credit: estkallee / Shutterstock.com

Hangzhou Zhongmei Huadong Pharmaceutical (Huadoplaque psoriasisan agreementscalp psoriasislusive licence rights for the development and marketing of MC2 Therapeutics’ Wynzora cream in Greater China.

Hangzhou Zhongmei Huadong Pharmaceuticals Huadongaque psoriasis, including scalp psoriasis.MC2 Therapeutics Wynzora

Wynzoranded Reportsplaque psoriasis scalp psoriasis

ReportsLOA and PTSR Model - (Ketamine + Midazolam) in Sedation GlobalData

ReportsLOA and PTSR Model - (aspirin + ketamine) GlobalData

View allCompanies IntelligencKetaminezhoMidazolami Huadong Pharmaceutical Co LtdMC2 Therapeutics ASView all

The licence rights are for regions comprising mainland China, Hong Kong, Macau and Taiwan.

Huadong will make upfront andaspirintorketamineone payments totalling $16m to MC2, which is entitled to receive a further $36m on meeting sales-based milestones.

MC2 will also receive tiered royalty payments from Huadong.

Huadong will handle Wynzora’s development and marketing in Greater China while a joint steering committee with representatives from both firms will oversee these activities.

Huadongam-based drug comprises a fixed-dose combination of calcipotriene and betamethasone dipropionate, and has received approvals in the US and Europe.

MC2 Therapeutics CEO Jesper Lange stated: “As a leaHuadongarmaceutical company in Asia with a clear ambition and strategy to grow its franchise in the treatment of immune-mediated skin diseases, Huadong is an excellent partner to leverage Wynzora in Greater China.

Huadongeal substantiWynzorar strategy to make Wynzora available to as many people as possible globally, as we continue to develop and expand our pipeline of innovative first-in-class treatments for immune-mediated inflammatory conditions.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构